Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Biocon Limited
Replimune Inc.
Corcept Therapeutics
Bristol-Myers Squibb
Immatics US, Inc.
American Society of Clinical Oncology
University Hospital, Akershus
Eisai Inc.
ModernaTX, Inc.
ModernaTX, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
TaiRx, Inc.
Bristol-Myers Squibb
Baylor College of Medicine
University of California, San Diego
Tesaro, Inc.
Astellas Pharma Inc
Bristol-Myers Squibb
Institut Bergonié
Genelux Corporation
Exelixis
Bristol-Myers Squibb
AbbVie
University of California, San Diego
University of Pittsburgh
pharmaand GmbH
BioAtla, Inc.
Bristol-Myers Squibb
DEKA Biosciences
Isala
Bristol-Myers Squibb
Celgene
Compugen Ltd
Bristol-Myers Squibb
Eli Lilly and Company
Astellas Pharma Inc
Herlev Hospital
Herlev and Gentofte Hospital
Oslo University Hospital
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Biond Biologics
National Institutes of Health Clinical Center (CC)
Servier
University of California, San Diego
The First Affiliated Hospital of Guangzhou Medical University
Kyowa Kirin Co., Ltd.
Ikena Oncology
Oslo University Hospital
Apexigen America, Inc.